New chair for the BioIndustry Association
July 1, 2013The BioIndustry Association has appointed Dr Edward Hodgkin as its new chairman, effective from October this year.Hodgkin succeeds Tim Edwards, …
Lords: ‘Simplify pharma regulation’
July 1, 2013Sales and Marketing Lords, NICE, pharma, regulation
Investors are not putting their money into the UK’s regenerative medicine sector because of the high failure rate when it …
‘Three-person’ IVF consultation
June 28, 2013Research and Development, Sales and Marketing DoH, HFEA, IVF
The Department of Health is to publish draft guidelines later this year on a controversial IVF-based technique which would lead …
Survey: ‘Consultants prefer mailshots’
June 28, 2013Medical Communications, Sales and Marketing Onyx, digital, mailshots
Pharma should use standard marketing activities such as mailshots if they want to promote their products effectively in UK secondary …
Diabetes vaccine trial posts positive results
June 28, 2013Research and Development, Sales and Marketing TOL-3021, Vaccine, diabetes
A groundbreaking new study suggests that the body’s immune system can be taught to reverse the effects of type 1 …
Life appoints new account manager
June 28, 2013Medical Communications, Research and Development, Sales and Marketing Life, mead
Creative comms agency Life has expanded its client service team with the appointment of a new account manager.Kirsty Mead joins Life from Seven …
FDA issues final guidance on heparin testing
June 27, 2013Manufacturing and Production, Sales and Marketing FDA, heparin
Five years after the adulterated heparin scandal that claimed the lives of dozens of people in the US alone, the …
ImmTAC deal for Immunocore
June 27, 2013Research and Development, Sales and Marketing Genentech, ImmTAC, oxford biotech
Oxford-based biotech company Immunocore has signed what could be a $300 million deal with Genentech to discover and bring to …
Oxford BioTherapeutics hires chairman
June 27, 2013Manufacturing and Production, Research and Development, Sales and Marketing Oxford Biotherapeutics, morton
Biotech firm Oxford BioTherapeutics has appointed Bryan Morton to be the company’s new non-executive chairman. Morton has over 30 years’ …
Contract research news in brief
June 27, 2013Research and Development PRA International, Parexel, Quanticate, TKL, WIL Research
A round-up of recent developments in the contract research sector, including KKR’s acquisition of PRA, a new Parexel business unit …
Astellas in $500m deal with Cytokinetics
June 27, 2013Sales and Marketing Astellas, cytokinetics
Astellas Pharma could pay out $40 million over the next two years to US firm Cytokinetics as part of a …
Heart failure treatment given Breakthrough Status
June 27, 2013Sales and Marketing Breakthrough Therapy Designation, Novartis, RLX03O, serelaxin
Novartis’ new treatment for heart failure has been granted Breakthrough Therapy designation status by the FDA. RLX030 (serelaxin) is for …
Xtandi gets EU approval
June 26, 2013Sales and Marketing Astellas, FDA, Xtandi
Astellas Pharma’s Xtandi has been approved in the European Union for the treatment of adult men with advanced prostate cancer, …
NICE finalises tamoxifen guidance
June 26, 2013Sales and Marketing Evista, NICE, lilly, tamoxifen
Women at risk of breast cancer can now be offered a daily pill on the NHS to stop the disease …
Allergan announces new president
June 26, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, ingram
Allergan has hired Douglas Ingram to be its president and lead the company’s global commercial operations. In this newly established …
Sanofi chief executive to lead EFPIA
June 26, 2013Research and Development, Sales and Marketing EFPIA, GSK, Sanofi, Viehbacher, Witty
Chief executive of Sanofi Christopher Viehbacher has been elected to serve as president of the European Federation of Pharmaceutical Industries …
Ranbaxy facing another facility problem?
June 26, 2013Manufacturing and Production FDA, Ranbaxy
Another facility operated by Ranbaxy Laboratories in India is reported to have failed an inspection by the FDA, potentially adding …
NICE completes Forxiga U-turn
June 26, 2013Sales and Marketing BMS, Forxiga, NICE
Bristol-Myers Squibb and AstraZeneca are celebrating after NICE reversed its decision from earlier this year and is now recommending their …
Merck Serono censured over calls
June 25, 2013Medical Communications, Sales and Marketing ABPI, Erbitux, Merck Serono, PMCPA
A Merck Serono medical representative has been accused of ‘harassing’ an anonymous health professional by requesting a meeting every month …
Lilly diabetes drug beats rivals
June 25, 2013Sales and Marketing BMS, diabetes, dulaglutide, lilly
New clinical trial results have shown Lilly’s investigational type 2 diabetes drug has beaten its three nearest rivals in reducing …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
